The Childhood Limb-Girdle Muscular Dystrophies

Seminars in Pediatric Neurology

Volumn 13, Issue 2, 2006, Pages 104-114

  Straub, Volker ^a   Bushby, Kate ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

dystrophin glycoprotein complex; genetics; limb girdle muscular dystrophy; management; translational research

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; GLYCOPROTEIN; INHALATION ANESTHETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; SARCOGLYCAN;

ANESTHESIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CHEST INFECTION; CHILDHOOD DISEASE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; ELECTROPHYSIOLOGY; GASTROINTESTINAL SYMPTOM; GENERAL ANESTHESIA; GENETIC DISORDER; GENETICS; HEART PROTECTION; HISTOLOGY; HUMAN; IMMUNIZATION; IMMUNOASSAY; LABORATORY TEST; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCULOSKELETAL SYSTEM; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PELVIC GIRDLE; PHENOTYPE; PHYSICAL EXAMINATION; QUALITY OF LIFE; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; REVIEW; SHOULDER; SKELETAL MUSCLE; SPECTRUM; SYMPTOM; SYSTEMIC DISEASE;

CHILD; CHILD, PRESCHOOL; HUMANS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE;

EID: 33749247975     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2006.06.006     Document Type: Review

References (75)

1. Bönnemann C.G., and Finkel R.S. Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. Semin Pediatr Neurol 9 (2002) 81-99
2. Nowak K., McCullagh K., Poon E., et al. Muscular dystrophies related to the cytoskeleton/nuclear envelope. Novartis Found Symp 264 (2005) 98-111 discussion 112-117, 227-230
3. Baghdiguian S., Richard I., Martin M., et al. Pathophysiology of limb girdle muscular dystrophy type 2A: Hypothesis and new insights into the IkappaBalpha/NF-kappaB survival pathway in skeletal muscle. J Mol Med 79 (2001) 254-261
4. Endo T. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies. Acta Myol 24 (2005) 64-69
5. Frosk P., Weiler T., Nylen E., et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 70 (2002) 663-672
6. Moreira E.S., Wiltshire T.J., Faulkner G., et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 24 (2000) 163-166
7. Udd B., Vihola A., Sarparanta J., et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 64 (2005) 636-642
8. Angelini C. Limb-girdle muscular dystrophies: Heterogeneity of clinical phenotypes and pathogenetic mechanisms. Acta Myol 23 (2004) 130-136
9. Starling A., Kok F., Passos-Bueno M.R., et al. A new form of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome 4p21. Eur J Hum Genet 12 (2004) 1033-1040
10. Nigro V. Molecular bases of autosomal recessive limb-girdle muscular dystrophies. Acta Myol 22 (2003) 35-42
11. Fulizio L., Chiara Nascimbeni A., Fanin M., et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat 25 (2005) 82-89
12. Walter M.C., Petersen J.A., Stucka R., Fischer D., et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 41 (2004) e50
13. Mercuri E., Jungbluth H., and Muntoni F. Muscle imaging in clinical practice: diagnostic value of muscle magnetic resonance imaging in inherited neuromuscular disorders. Curr Opin Neurol 18 (2005) 526-537
14. Mercuri E., Bushby K., Ricci E., et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 15 (2005) 164-171
15. Fischer D., Walter M.C., Kesper K., et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 252 (2005) 538-547
16. Georgieva B., Todorova A., Tournev I., et al. 550delA mutation in the calpain 3 (CAPN3) gene: DMD/BMD, SMA, or LGMD2A-Clinically misdiagnosed cases. Am J Med Genet A 136 (2005) 399-400
17. Starling A., de Paula F., Silva H., et al. Calpainopathy: How broad is the spectrum of clinical variability?. J Mol Neurosci 21 (2003) 233-236
18. Benedetti S., and Merlini L. Laminopathies: From the heart of the cell to the clinics. Curr Opin Neurol 17 (2004) 553-560
19. Decostre V., Ben Yaou R., and Bonne G. Laminopathies affecting skeletal and cardiac muscles: Clinical and pathophysiological aspects. Acta Myol 24 (2005) 104-109
20. Broers J.L., Kuijpers H.J., Ostlund C., et al. Both lamin A and lamin C mutations cause lamina instability as well as loss of internal nuclear lamin organization. Exp Cell Res 304 (2005) 582-592
21. Denecke J., Brune T., Feldhaus T., et al. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): Insights into the pathophysiology of HGPS. Hum Mutat 27 (2006) 524-531
22. Pollex R.L., and Hegele R.A. Hutchinson-Gilford progeria syndrome. Clin Genet 66 (2004) 375-381
23. Hegele R. LMNA mutation position predicts organ system involvement in laminopathies. Clin Genet 68 (2005) 31-34
24. Mercuri E., Brown S.C., Nihoyannopoulos P., et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle Nerve 31 (2005) 602-609
25. Meune C., Van Berlo J.H., Anselme F., et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 354 (2006) 209-210
26. Perrot A., Sigusch H.H., Nagele H., et al. Genetic and phenotypic analysis of dilated cardiomyopathy with conduction system disease: Demand for strategies in the management of presymptomatic lamin A/C mutant carriers. Eur J Heart Fail 8 (2006) 484-493
27. Sylvius N., and Tesson F. Lamin A/C and cardiac diseases. Curr Opin Cardiol 21 (2006) 159-165
28. van der Kooi A.J., van Meegen M., Ledderhof T.M., et al. Genetic localization of a newly recognized autosomal dominant limb- girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet 60 (1997) 891-895
29. Raffaele Di Barletta M., Ricci E., et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 66 (2000) 1407-1412
30. Galbiati F., Volont D., Minetti C., et al. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. J Biol Chem 274 (1999) 25632-25641
31. Woodman S.E., Sotgia F., Galbiati F., et al. Caveolinopathies: Mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62 (2004) 538-543
32. Fee D.B., So Y.T., Barraza C., et al. Phenotypic variability associated with Arg26Gln mutation in caveolin3. Muscle Nerve 30 (2004) 375-378
33. Minetti C., Sotgia F., Bruno C., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18 (1998) 365-368
34. Alias L., Gallano P., Moreno D., et al. A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia. Neuromuscul Disord 14 (2004) 321-324
35. Merlini L., Carbone I., Capanni C., et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry 73 (2002) 65-67
36. Hayashi T., Arimura T., Ueda K., et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 313 (2004) 178-184
37. Kubisch C., Ketelsen U.P., Goebel I., et al. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol 57 (2005) 303-304
38. Kubisch C., Schoser B.G., von During M., et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 53 (2003) 512-520
39. Torbergsen T. Rippling muscle disease: A review. Muscle Nerve Suppl 11 (2002) S103-S107
40. Messina D.N., Speer M.C., Pericak-Vance M.A., et al. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 61 (1997) 909-917
41. Palenzuela L., Andreu A.L., Gamez J., et al. A novel autosomal dominant limb-girdle muscular dystrophy (LGMD 1F) maps to 7q32.1-32.2. Neurology 61 (2003) 404-406
42. Michele D.E., and Campbell K.P. Dystrophin-glycoprotein complex: Post-translational processing and dystroglycan function. J Biol Chem 278 (2003) 15457-15460
43. Grewal P.K., and Hewitt J.E. Glycosylation defects: A new mechanism for muscular dystrophy?. Hum Mol Genet 12 (2003) R259-R264
44. Hewitt J.E., and Grewal P.K. Glycosylation defects in inherited muscle disease. Cell Mol Life Sci 60 (2003) 251-258
45. Jones K.J., Morgan G., Johnston H., et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: Case series and review. J Med Genet 38 (2001) 649-657
46. Crosbie R.H., Lim L.E., Moore S.A., et al. Molecular and genetic characterization of sarcospan: Insights into sarcoglycan-sarcospan interactions. Hum Mol Genet 9 (2000) 2019-2027
47. Hack A.A., Cordier L., Shoturma D.I., et al. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A 96 (1999) 10723-10728
48. Durbeej M., and Campbell K.P. Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 12 (2002) 349-361
49. Wheeler M.T., and McNally E.M. Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med 13 (2003) 238-243
50. Frosk P., Greenberg C.R., Tennese A.A., et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat 25 (2005) 38-44
51. Poppe M., Bourke J., Eagle M., et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol 56 (2004) 738-741
52. Balci B., Uyanik G., Dincer P., et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 15 (2005) 271-275
53. Dincer P., Balci B., Yuva Y., et al. A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of alpha-dystroglycan. Neuromuscul Disord 13 (2003) 771-778
54. Bushby K., Anderson L.V., Pollitt C., et al. Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2. Brain 121 (1998) 581-588
55. Sveen M.L., Schwartz M., and Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 59 (2006) 808-815
56. Richard I., Broux O., Allamand V., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81 (1995) 27-40
57. Saenz A., Leturcq F., Cobo A.M., et al. LGMD2A: Genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 128 (2005) 732-742
58. Taveau M., Bourg N., Sillon G., et al. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol 23 (2003) 9127-9135
59. Sorimachi H., Ono Y., and Suzuki K. Skeletal muscle-specific calpain, p94, and connectin/titin: Their physiological functions and relationship to limb-girdle muscular dystrophy type 2A. Adv Exp Med Biol 481 (2000) 383-395 discussion 395-397
60. Richard I., Roudaut C., Saenz A., et al. Calpainopathy-A survey of mutations and polymorphisms. Am J Hum Genet 64 (1999) 1524-1540
61. Pollitt C., Anderson L.V., Pogue R., et al. The phenotype of calpainopathy: Diagnosis based on a multidisciplinary approach. Neuromuscul Disord 11 (2001) 287-296
62. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423 (2003) 168-172
63. Nguyen K., Bassez G., Bernard R., et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 26 (2005) 165
64. Walter M.C., Braun C., Vorgerd M., et al. Variable reduction of caveolin-3 in patients with LGMD2B/MM. J Neurol 250 (2003) 1431-1438
65. Anderson L.V., Harrison R.M., Pogue R., et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 10 (2000) 553-559
66. Cenacchi G., Fanin M., De Giorgi L.B., et al. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 58 (2005) 190-195
67. Schoser B.G., Frosk P., Engel A.G., et al. Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol 57 (2005) 591-595
68. Haravuori H., Vihola A., Straub V., et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene. Neurology 56 (2001) 869-877
69. Bushby K., and Straub V. Nonmolecular treatment for muscular dystrophies. Curr Opin Neurol 18 (2005) 511-518
70. Bushby K., Muntoni F., and Bourke J.P. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy, 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 13 (2003) 166-172
71. Wallgren-Pettersson C., Bushby K., Mellies U., et al. ENMC workshop: Ventilatory support in congenital neuromuscular disorders-Congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands. Neuromuscul Disord 14 (2004) 56-69
72. Jensen M.P., Abresch R.T., Carter G.T., et al. Chronic pain in persons with neuromuscular disease. Arch Phys Med Rehabil 86 (2005) 1155-1163
73. Eagle M. Report on the muscular dystrophy campaign workshop: Exercise in neuromuscular diseases, Newcastle, January 2002. Neuromuscul Disord 12 (2002) 975-983
74. Klingler W., Lehmann-Horn F., and Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15 (2005) 195-206
75. von der Hagen M., Schallner J., Kaindl A.M., et al. Facing the genetic heterogeneity in neuromuscular disorders: linkage analysis as an economic diagnostic approach towards the molecular diagnosis. Neuromuscul Disord 16 (2006) 4-13